Neumora shares sink following Phase III flop in MDD
The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to meet its primary and secondary endpoint.
Healthcare
Investment surges, hurdles and emerging innovations in neuroscience
Astellas withdraws Europe ACP application for AMD treatment
Takeda and BMC partner to decarbonise US healthcare sector
CPHI Europe: how AI can drive growth in the nutraceutical space
CPHI Europe: strategies to navigate nitrosamines risk evaluation
DPV set to acquire Lumos Pharma for $38m
TheracosBio and BAMCO to bring BRENZAVVY to sub-Saharan Africa for T2D
